Biomarin Pharmaceutical BMRN
NASDAQ BMRN
$55.21 -1.23 (-2.18%)
At close: Oct 21, 2026 · 4:00 PM EDT

Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009)

Updated

Biomarin Pharmaceutical (BMRN) posted Current Deferred Revenue of $86,000 for Q4 2009.

Analysis

Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Biomarin Pharmaceutical 10.64 Bn 4.51 Bn 786.91 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2009 86,000.00
API Access

Biomarin Pharmaceutical Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=BMRN&period=max&api_key=YOUR_API_KEY